CoChat

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Open access
Gouni-Berthold, Ioanna, Alexander, Veronica J, Yang, Qingqing, Hurh, Eunju, Steinhagen-Thiessen, Elisabeth, Moriarty, Patrick M, Hughes, Stephen G, Gaudet, Daniel, Hegele, Robert A, O'Dea, Louis St L, Stroes, Erik S G, Tsimikas, Sotirios, Witztum, Joseph L, Agarwal, Abhay, Ballantyne, Christie, Baum, Seth, Bergeron, Jean, Bruckert, Eric, Burdick, Richard, Castro-Cabezas, Manuel, Cervi, Mark, Corder, Clinton, DuFour, Robert, Farrington, Cecil Murray, Francis, Gordon, Galitz, Lawrence, Hamstead, Steven, Hemphill, Linda, Huffman, Cynthia, Issa, Basil, Julius, Ulrich, Kane, John, Krempf, Michel, Martin, Steven, Powell, James, Shultzaberger, Richard, Thompson, Craig, Thompson-Hargrave, Letitia, Toth, Peter, Turner, Traci, Valero, Rene, Verges, Bruno, Visseren, Frank L J, Vyas, Pankaj, Yataco, Alberto · 2021 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background Volanesorsen is an antisense oligonucleotide that targets hepatic apolipoprotein C-III synthesis and reduces plasma triglyceride concentration. The aim of this study was to explore the safety and efficacy of volanesorsen in patients with multifactorial chylomicronaemia syndrome.Methods The COMPASS trial was a randomised, placebo-controlled, double-blind, phase 3 study done at 38 international clinical sites in Canada, France, Germany, the Netherlands, UK, and USA. Eligible patients were aged 18 years or older with multifactorial severe hypertriglyceridaemia or familial chylomicronaemia syndrome, who had a BMI of 45 kg/m 2 or less and fasting plasma triglyceride of 500 mg/dL or higher. Patients were randomly assigned (2:1) with an interactive response system using an allocation sequence and permuted block randomisation to receive subcutaneous volanesorsen (300 mg) or a matched volume of placebo (1·5 mL) once a week for 26 weeks. After 13 weeks of treatment, dosing was changed to 300 mg of volanesorsen or placebo every 2 weeks for all patients, except those who had completed 5 months or more of treatment as of May 27, 2016. Participants, investigators, sponsor personnel, and clinical research staff were all masked to the treatment assignments. The primary outcome was percentage change from baseline to 3 months in fasting triglyceride in the full analysis set (all patients who were randomly assigned and received at least one dose of study drug and had a baseline fasting triglyceride assessment). This trial is registered with ClinicalTrials.gov, NCT02300233 (completed).Findings Between Feb 5, 2015, and Jan 24, 2017, 408 patients were screened for eligibility. 294 were excluded and 114 randomly assigned to receive either volanesorsen (n=76) or placebo (n=38). One patient in the volanesorsen group discontinued before receiving the study drug. The total number of dropouts was 28 (four in the placebo group and 24 in the treatment group). Volanesorsen reduced mean plasma triglyceride concentration by 71·2% (95% CI -79·3 to -63·2) from baseline to 3 months compared with 0·9% (-13·9 to 12·2) in the placebo group (p<0·0001), representing a mean absolute reduction of fasting plasma triglycerides of 869 mg/dL (95% CI -1018 to -720; 9·82 mmol/L [-11·51 to -8·14]) in volanesorsen compared with an increase in placebo of 74 mg/dL (-138 to 285; 0·83 mmol/L [-1·56 to 3·22]; p<0·0001). In the key safety analysis, five adjudicated events of acute pancreatitis occurred during the study treatment period, all in three of 38 patients in the placebo group. The most common adverse events were related to tolerability and included injection-site reactions (average of 24% of all volanesorsen injections vs 0·2% of placebo injections), which were all mild or moderate. One participant in the volanesorsen group had a platelet count reduction to less than 50 000 per μL and one patient had serum sickness, both of which were regarded as serious adverse events.Interpretation Volanesorsen significantly reduced triglyceride concentrations in patients with multifactorial chlyomicronaemia and might reduce acute pancreatitis events in these patients.Funding Ionis Pharmaceuticals and Akcea Therapeutics.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(21)00046-2

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 32 references

Cited by

See all 232

Metadata

Authors
Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., Stroes, E. S. G., Tsimikas, S., Witztum, J. L., Agarwal, A., Ballantyne, C., Baum, S., Bergeron, J., Bruckert, E., Burdick, R., Castro-Cabezas, M., Cervi, M., Corder, C., DuFour, R., Farrington, C. M., Francis, G., Galitz, L., Hamstead, S., Hemphill, L., Huffman, C., Issa, B., Julius, U., Kane, J., Krempf, M., Martin, S., Powell, J., Shultzaberger, R., Thompson, C., Thompson-Hargrave, L., Toth, P., Turner, T., Valero, R., Verges, B., Visseren, F. L. J., Vyas, P., & Yataco, A.
Affiliations
  • Ionis Pharmaceuticals (United States) (US)
  • University of Kansas Medical Center (US)
  • Université de Montréal (CA)
  • Western University (CA)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • University of California San Diego (US)
Corresponding author
Witztum, Joseph L
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2021-05
Volume
9
Issue
5
Pages
264-275
ISSN
2213-8587 (ISSN-L)
OpenAlex
W3146122039
Cited by
232
References
32
Citations by year
2026: 37 · 2025: 50 · 2024: 46 · 2023: 40 · 2022: 39 · 2021: 20
FWCI
24.27
Type
journal article
Language
en
Open access
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
  • Ionis Pharmaceuticals
  • Akebia Therapeutics
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
Keywords
volanesorsen, apolipoprotein C-III, antisense oligonucleotides, hypertriglyceridemia, fasting plasma triglycerides, triglyceride lowering, drug safety, adverse events, drug discontinuation, COMPASS trial, hypertriglyceridemia treatment
MeSH terms
Adult, Aged, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Causality, Oligonucleotides, Antisense, Treatment Outcome, Internationality, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(21)00046-2
The paper
Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., Stroes, E. S. G., Tsimikas, S., Witztum, J. L., Agarwal, A., Ballantyne, C., Baum, S., Bergeron, J., Bruckert, E., Burdick, R., . . . Yataco, A. (2021). Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(21)00046-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.